CCND1 and neoplasm: Accordingly, the frequencies of Cyclin D1-positive nuclei in tumor area were significantly lower in vevorisertib (20.1 ± 4.0, p = 0.0420) and in the vevorisertib + sorafenib group (16.1 ± 3.1, p = 0.0073) compared to the control group (58.9 ± 7.6), Figure 3a,b.